These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 24347384)

  • 1. Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic renal cell carcinoma.
    Halabi S; Rini B; Escudier B; Stadler WM; Small EJ
    Cancer; 2014 Jan; 120(1):52-60. PubMed ID: 24347384
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
    Grünwald V; Lin X; Kalanovic D; Simantov R
    Eur Urol; 2016 Dec; 70(6):1006-1015. PubMed ID: 27238653
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival.
    Escudier B; Bellmunt J; Négrier S; Bajetta E; Melichar B; Bracarda S; Ravaud A; Golding S; Jethwa S; Sneller V
    J Clin Oncol; 2010 May; 28(13):2144-50. PubMed ID: 20368553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bevacizumab in combination with IFN-α in metastatic renal cell carcinoma: the AVOREN trial.
    Melichar B; Procházková-Študentová H; Vitásková D
    Expert Rev Anticancer Ther; 2012 Oct; 12(10):1253-61. PubMed ID: 23136836
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multinational phase II trial of bevacizumab with low-dose interferon-α2a as first-line treatment of metastatic renal cell carcinoma: BEVLiN.
    Melichar B; Bracarda S; Matveev V; Alekseev B; Ivanov S; Zyryanov A; Janciauskiene R; Fernebro E; Mulders P; Osborne S; Jethwa S; Mickisch G; Gore M; van Moorselaar RJ; Staehler M; Magne N; Bellmunt J;
    Ann Oncol; 2013 Sep; 24(9):2396-402. PubMed ID: 23803225
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206.
    Rini BI; Halabi S; Rosenberg JE; Stadler WM; Vaena DA; Archer L; Atkins JN; Picus J; Czaykowski P; Dutcher J; Small EJ
    J Clin Oncol; 2010 May; 28(13):2137-43. PubMed ID: 20368558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FDA drug approval summary: bevacizumab plus interferon for advanced renal cell carcinoma.
    Summers J; Cohen MH; Keegan P; Pazdur R
    Oncologist; 2010; 15(1):104-11. PubMed ID: 20061402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of progression-free survival as a surrogate end-point for overall survival in patients with metastatic renal cell carcinoma.
    Négrier S; Bushmakin AG; Cappelleri JC; Korytowsky B; Sandin R; Charbonneau C; Michaelson MD; Figlin RA; Motzer RJ
    Eur J Cancer; 2014 Jul; 50(10):1766-1771. PubMed ID: 24768571
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial.
    Rini BI; Bellmunt J; Clancy J; Wang K; Niethammer AG; Hariharan S; Escudier B
    J Clin Oncol; 2014 Mar; 32(8):752-9. PubMed ID: 24297945
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progression-free survival as a predictor of overall survival in metastatic renal cell carcinoma treated with contemporary targeted therapy.
    Heng DY; Xie W; Bjarnason GA; Vaishampayan U; Tan MH; Knox J; Donskov F; Wood L; Kollmannsberger C; Rini BI; Choueiri TK
    Cancer; 2011 Jun; 117(12):2637-42. PubMed ID: 21656741
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overall survival in patients with metastatic renal cell carcinoma initially treated with bevacizumab plus interferon-α2a and subsequent therapy with tyrosine kinase inhibitors: a retrospective analysis of the phase III AVOREN trial.
    Bracarda S; Bellmunt J; Melichar B; Négrier S; Bajetta E; Ravaud A; Sneller V; Escudier B
    BJU Int; 2011 Jan; 107(2):214-9. PubMed ID: 20942831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bevacizumab: in first-line treatment of advanced and/or metastatic renal cell carcinoma.
    Frampton JE; Keating GM
    BioDrugs; 2008; 22(2):113-20. PubMed ID: 18345708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.
    Choueiri TK; Garcia JA; Elson P; Khasawneh M; Usman S; Golshayan AR; Baz RC; Wood L; Rini BI; Bukowski RM
    Cancer; 2007 Aug; 110(3):543-50. PubMed ID: 17577222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II study of bevacizumab and everolimus as treatment for refractory metastatic renal cell carcinoma.
    Harshman LC; Barbeau S; McMillian A; Srinivas S
    Clin Genitourin Cancer; 2013 Jun; 11(2):100-6. PubMed ID: 23352238
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First-line bevacizumab combined with reduced dose interferon-alpha2a is active in patients with metastatic renal cell carcinoma.
    Melichar B; Koralewski P; Ravaud A; Pluzanska A; Bracarda S; Szczylik C; Chevreau C; Filipek M; Delva R; Sevin E; Négrier S; McKendrick J; Santoro A; Pisa P; Escudier B
    Ann Oncol; 2008 Aug; 19(8):1470-1476. PubMed ID: 18408224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized phase II trial of interleukin-2 and interferon-α plus bevacizumab versus interleukin-2 and interferon-α in metastatic renal-cell carcinoma (mRCC): results from the Danish Renal Cancer Group (DaRenCa) study-1.
    Donskov F; Jensen NV; Smidt-Hansen T; Brøndum L; Geertsen P
    Acta Oncol; 2018 May; 57(5):589-594. PubMed ID: 29392960
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206.
    Rini BI; Halabi S; Rosenberg JE; Stadler WM; Vaena DA; Ou SS; Archer L; Atkins JN; Picus J; Czaykowski P; Dutcher J; Small EJ
    J Clin Oncol; 2008 Nov; 26(33):5422-8. PubMed ID: 18936475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytoreductive radiofrequency ablation in patients with metastatic renal cell carcinoma (RCC) with small primary tumours treated with sunitinib or interferon-α.
    Tsimafeyeu I; Zart JS; Chung B
    BJU Int; 2013 Jul; 112(1):32-8. PubMed ID: 23746142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bevacizumab plus interferon-α versus sunitinib for first-line treatment of renal cell carcinoma in Italy: a cost-minimization analysis.
    Ravasio R; Ortega C; Sabbatini R; Porta C
    Clin Drug Investig; 2011; 31(7):507-17. PubMed ID: 21627339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of serum CA9 in patients with metastatic clear cell renal cell carcinoma under targeted therapy.
    Gigante M; Li G; Ferlay C; Perol D; Blanc E; Paul S; Zhao A; Tostain J; Escudier B; Negrier S; Genin C
    Anticancer Res; 2012 Dec; 32(12):5447-51. PubMed ID: 23225450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.